Comparison between mycophenolate mofetil and azathioprine-based immunosuppressions in clinical lung transplantation

Journal of Heart and Lung Transplantation

Volumn 18, Issue 5, 1999, Pages 432-440

  Zuckermann, Andreas ^a   Klepetko, Walter ^a   Birsan, Tudor ^a   Taghavi, Sharokh ^a   Artemiou, Omeros ^a   Wisser, Wilfried ^a   Dekan, Gerhard ^a   Wolner, Ernst ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SURVIVAL; THROMBOCYTOPENIA; TRANSBRONCHIAL BIOPSY;

ADOLESCENT; ADULT; AZATHIOPRINE; BIOPSY; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; GRAFT REJECTION; HUMANS; IMMUNOGLOBULINS, THYROID-STIMULATING; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; INCIDENCE; LEUKOCYTE COUNT; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISOLONE; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032990042     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(99)00004-2     Document Type: Article

References (44)

1. Griffith B.P., Paradis I.L., Zeevi A., et al. Immunologically mediated disease of the airways after pulmonary transplantation. Ann Surg. 208:1988;371-378.
2. Wisser W., Wekerle T., Zlabinger G., et al. Influence of human leucocyte antigen matching on long-term outcome after lung transplantation. J Heart Lung Transplant. 15:1996;1209-1216.
3. Griffith B.P., Hardesty R.L., Armitage J.M., et al. Acute rejection of lung allografts with various immunosuppressive protocols. Ann Thorac Surg. 54:1992;846.
4. Griffith B.P., Hardesty R.L., Armitage J.M., et al. A decade of lung transplantation. Ann Thorac Surg. 218:1993;310.
5. Yousem S.A., Berry G.J., Brunt E., et al. A working formulation for the standarization of nomenclature in the diagnosis of heart and lung rejection lung rejection study group . Heart Transplant. 9:1990;593-601.
6. Yousem S.A., Berry G.J., Cagle P.T., et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection lung rejection study group . J Heart Lung Transplant. 15:1996;1-15.
7. Cooper J.D., Billingham M., Egan T., et al. A working formulation for the standarisation of the nomenclature and for clinical staging of chronic dysfunction of lung allografts. J Heart Lung Transplant. 12:1993;713.
8. Reichenspurner H., Girgis R.E., Robbins R.C., et al. Obliterative bronchiolitis after lung and heart-lung transplantation. Ann Thorac Surg. 60:1995;1845-1853.
9. Paradis IL, Yousem SA, Griffith BP. Airway obstruction and bronchiolitis obliterans after lung transplantation. In: King TE, eds. Bronchiolitis. Clinics in chest medicine. Philadelphia, PA: W.B. Saunders, 1993;24:751-778.
10. Bando K., Paradis I.L., Similo S., et al. Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg. 110:1995;4-14.
11. Starnes T.J., Lewiston N.J. Obliferative bronchiolitis. Grossman R.F., Maurer J.R. Pulmonary considerations in transplantation. Clinics in chest medicine. Vol. 2, no 2. 1990;309-321 W.B. Saunders, Philadelphia, PA.
12. Burke C.M., Yousem S.A., Corris P.A. Heart-lung transplantation. Epler G.R. Disease of the bronchioles. 1994;259-274 Raven Press, New York.
13. Lee W.A., Gu L., Miksztal A.R., et al. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res. 7:1990;161.
14. Eugui E.M., Almquist S.J., Muller C.D., et al. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acidin vitro role of deoxyguanosine nucleotide depletion . Scand J Immunol. 33:1991;161.
15. Hao L., Lafferty K.J., Allison A.C., et al. RS-61443 allows islet allografting and specific tolerance induction in adult mice. Transplant Proc. 22:1990;1659.
16. Platz K.P., Sollinger H.W., Hullett Da, et al. RS-61443, a new potent immunosuppressive agent. Transplantation. 51:1991;27.
17. D'Allesandro A.M., Rankin M., McVey J., et al. Prolongation of canine intestinal allograft survival with RS-61443, cyclosporine and prednisolone. Transplantation. 55:1993;695.
18. Platz K.P., Bechstein W.O., Eckhoff D.E., et al. RS-61443 reverses acute rejection in dogs. Surgery. 110:1991;736.
19. Sollinger H.W. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation. 60:1995;225-232.
20. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric transplantation. Transplantation. 61:1996;1029-1037.
21. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet. 345:1995;1321-1325.
22. Trulock E.P., Ettinger N.A., Brunt E.M., et al. The role of transbronchial lung biopsy in treatments of lung transplant recipients. Chest. 102:(4):1992;1049-1054.
23. Hosenpud J.D., Novick R.J., Breen T.J., Keck B., Daily P. The registry of the International Society of Heart and Lung Transplantation fourteenth officical report - 1997 . J Heart Lung Transplant. 16:1997;691-712.
24. O'Hair D.P., Umana J.P., McGregor C., et al. The International Society for Heart and Lung Transplantation 17th annual meeting and scientific sessions. London, England, April 2-5, 1997. (abstracts) J Heart Lung Transplant. 16:1997;75.
25. Ross D.J., Waters P.F., Levine M., et al. The International Society for Heart and Lung Transplantation 17th annual meeting and scientific sessions. London, England, April 2-5, 1997. (abstracts) J Heart Lung Transplant. 16:1997;76.
26. Armitage J.M., Kormos R.L., Morita S., et al. Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. Ann Thorac Surg. 54:1992;205.
27. Sharples L.D., Tamm M., McNeil, et al. Development of bronchiolitis obliterans syndrome in recipients of heart-lung transplantation - early risk factors. Transplantation. 61:1996;560-566.
28. Bando K., Paradis I.L., Komatsu K., et al. Analysis of time dependent risk factors for infection, rejection, and death after pulmonary transplantation. J Thorac Cardiovasc Surg. 109:1995;49-59.
29. Yousem S.A., Dauber J.A., Keenan R., et al. Does histologic acute rejection in lung allograft predict the development of bronchiolitis obliterans? Transplantation. 52:1991;306-309.
30. Yousem S.A. Significance of clinically silent untreated mild acute cellular rejection in lung allograft recipients. Hum Pathol. 27:1996;269-273.
31. Duncan S.R., Grgurich W.F., Iaceno A.T., et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med. 150:1994;146-152.
32. Kriett J.M., Smith C.M., Hayden A.M., et al. Lung transplantation without the use of antithymocyte antibody preparations. J Heart Lung Transplant. 12:1993;915-922.
33. Merigan T.C., Renlund D.G., Keay S., et al. A controlled randomised trial of propylactic ganciclovir for cytomegalovirus disease after heart transplantation. N Engl J Med. 326:1992;1182-1186.
34. Verneir I., Giraud P., Eche J.P., et al. Hematological side effects of antilymphocyte globulins prevalence and impact on therapeutic protocol . Transpl Proc. 17:1985;2765-2766.
35. Schwartz R., Dameshek W. Drug induced immunological tolerance. Nature. 183:1959;1682-1683.
36. Taylor D.O., Ensley R.D., Olsen S.L., et al. Mycophenolate mofetil (RS-61443) Preclinical, clinical, and three-year experience in heart transplantation . J Heart Lung Transplant. 13:1994;571-582.
37. Mycophenolate mofetil for the treatment of refractory, acute cellular renal transplant rejection. Transplantation. 61:1996;722-729.
38. Klintmalm G.B., Ascher N.L., Busuttil R.W., et al. RS-61443 for treatment-resistant human liver rejection. Transpl Proc. 25:1993;697.
39. Whyte R.I., Rossi S.J., Mulligan M.S., et al. Mycophenolate mofetil for obliterative bronchiolitis syndrome afterlung transplantation. Ann Thorac Surg. 64:1997;945-948.
40. Speich R., Boehler A., Thurnheer R., Weder W. Salvage therapy for lung transplant bronchiolitis obliterans. Transplantation. 64:1997;533-535.
41. Gross D.C., Sasaki T.M., Buick M.K., Light J.A. Acute respiratory failure and pulmonary fibrosis secondary to administration of mycophenolate mofetil. Transplantation. 64:1997;1607-1609.
42. Meiser B., Überfuhr P., Pfeiffer M., et al. The International Society for Heart and Lung Transplantation 17th annual meeting and scientific sessions. London, England,April 2-5, 1997. (abstracts) J Heart Lung Transplant. 16:1997;44.
43. Spino M. Pharmacokinetics of drugs in cystic fibrosis. Clin Rev Allergy. 9:1991;169-210.
44. Tan K.K., Trull A.K., Hue K.L., et al. Pharmacokinetics of cyclosporine in heart and lung transplant candidates and recipients with cystic fibrosis and Eisenmenger's syndrome. Clin Pharmacol Ther. 53:1993;544-554.